Related content

Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers

By Gassó Patricia   Papagianni Katerina   Mas Sergi   de Bobadilla Ramón Fernández   Arnaiz Joan Albert   Bernardo Miquel   Lafuente Amalia  

Pharmacogenomics, Vol. 14, Iss. 13, 2013-10 ,pp. : 1551-1563

Future Medicine

Access to resources Recommend Favorite

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

By Kirchheiner J.  

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 267-278

Adis International

Access to resources Recommend Favorite

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers

By LLerena Adrian   Dorado Pedro   Ramírez Ronald   Calzadilla Luis R   Peñas-LLedó Eva   Álvarez Mayra   Naranjo María EG   González Idilio   Pérez Bárbaro  

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 1973-1977

Future Medicine

Access to resources Recommend Favorite

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

By Sehrt Daniel   Meineke Ingolf   Tzvetkov Mladen   Güültepe Senol   Brockmööller Jüürgen  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 783-795

Future Medicine

Access to resources Recommend Favorite

Allele Frequencies of CYP2D6, CYP3A5 and DPYD Genes Polymorphisms in the Healthy Yakut Population

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 14, Iss. 1, 2017-01 ,pp. : 50-55

Bentham Science Publishers

Access to resources Recommend Favorite